AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. They are also selectively active in the areas of autoimmunity, neuroscience and infection. They build their own capabilities by collaborating with world-renowned scientists and academic institutions, and partner with like-minded, science-led companies. AstraZeneca Australia, have been working to deliver the best value to patients for more than 60 years, and they push the boundaries of science to deliver life-changing medicines..
Live webinar - COPD and cardiovascular risk: The deadly duo - 17 April 2024
In this webinar GP Conjoint A/Prof Chee Khoo and Conjoint A/Prof Belinda Cochrane review latest recommendations for COPD management and describe the actions you can take to reduce the impact of comorbid cardiovascular risk in patients with COPD.
Clinical audit: Managing the deadly duo of COPD and cardiovascular risk
In this clinical audit, you will identify patients with COPD who have a history of moderate to severe exacerbations in the past 12 months and an increased risk of cardiovascular events. You will consider how your patient’s self-management behaviours, inhaled COPD medications and prescribed non-pharmacological treatments could be further optimised, in line with evidence-based guidelines, to improve symptom control and reduce the risk of further exacerbations.
